Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2025 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I ...

Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) and local biotechnology company Intra-ImmuSG ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

If phase 3 trials of MM120 (lysergide d-tartrate) for anxiety and depression are successful, could the LSD-based drug become ...

A groundbreaking trial found vagus nerve stimulation combined with therapy may fully eliminate PTSD symptoms in patients.

At the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, the Eye Care Network caught up with Jogin Desai. Dr. Desai is the founder of Eyestem Research, a biotechnology ...

A very low-carb diet significantly improved the pancreas’s ability to produce insulin in people with mild Type 2 diabetes ...

The National Institutes of Health (NIH) has laid off 250 more employees, with this round of cuts hitting 50 workers at the ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.